| Title |
Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach
|
|---|---|
| Published in |
Pharmaceutical Research, January 2017
|
| DOI | 10.1007/s11095-017-2096-4 |
| Pubmed ID | |
| Authors |
Dirk Bauerschlag, Ivo Meinhold-Heerlein, Nicolai Maass, Andreas Bleilevens, Karen Bräutigam, Wa’el Al Rawashdeh, Stefano Di Fiore, Anke Maria Haugg, Felix Gremse, Julia Steitz, Rainer Fischer, Elmar Stickeler, Stefan Barth, Ahmad Fawzi Hussain |
| Abstract |
Targeted theranostics is an alternative strategy in cancer management that aims to improve cancer detection and treatment simultaneously. This approach combines potent therapeutic and diagnostic agents with the specificity of different cell receptor ligands in one product. The success of antibody drug conjugates (ADCs) in clinical practice has encouraged the development of antibody theranostics conjugates (ATCs). However, the generation of homogeneous and pharmaceutically-acceptable ATCs remains a major challenge. The aim of this study is to detect and eliminate ovarian cancer cells on-demand using an ATC directed to EGFR. An ATC with a defined drug-to-antibody ratio was generated by the site-directed conjugation of IRDye®700 to a self-labeling protein (SNAP-tag) fused to an EGFR-specific antibody fragment (scFv-425). In vitro and ex vivo imaging showed that the ATC based on scFv-425 is suitable for the highly specific detection of EGFR(+) ovarian cancer cell, human tissues and ascites samples. The construct was also able to eliminate EGFR(+) cells and human ascites cells with IC50 values of 45-66 nM and 40-90 nM, respectively. Our experiments provide a framework to create a versatile technology platform for the development of ATCs for precise detection and treatment of ovarian cancer cells. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 5 | 13% |
| Researcher | 5 | 13% |
| Other | 4 | 10% |
| Student > Master | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 8 | 20% |
| Unknown | 10 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 20% |
| Unspecified | 5 | 13% |
| Chemistry | 4 | 10% |
| Medicine and Dentistry | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 14 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2018.
All research outputs
#18,604,390
of 23,045,021 outputs
Outputs from Pharmaceutical Research
#2,490
of 2,870 outputs
Outputs of similar age
#312,231
of 422,150 outputs
Outputs of similar age from Pharmaceutical Research
#23
of 26 outputs
Altmetric has tracked 23,045,021 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,870 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,150 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.